Sosei Looks To Add Value Through Pipeline Progress
Japan-based Sosei is building up its portfolio of in-house assets on top of technology and molecule licensing deals as it looks to create value over the next few years following the acquisition of Heptares, say executives.
You may also be interested in...
Japan-based Sosei's recent equity offering made its shareholder base more international and will help finance the evolution of the group's proprietary pipeline.
While it was not as affected as some other countries, Japan still had the pandemic to deal with and regulators responded while managing to keep up regular product review work, including several world-first approvals. Coronavirus vaccine roll-outs and the first general annual reimbursement price cut are on the cards for this year.
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.